AstraZeneca, GSK’s COVID-19 Therapies Lose Efficacy Against Omicron’s Subvariants
The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ:
SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $70
SVB Leerink analyst Andrew Berens maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $65 to $70.
Blood Clot Risk After First AstraZeneca COVID-19 Shot Very Small – UK Study Shows
A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine found
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a
AstraZeneca’s Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
AstraZeneca plc (NASDAQ: AZN) said that
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna’s Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours.
Why Are AstraZeneca Shares Trading Higher Today
Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease progression in patients with newly diagnosed
AstraZeneca, Merck Report LYNPARZA Plus Abiraterone Reduced Risk Of Disease Progression By 34% vs Standard Of Care In First-Line Metastatic Castration-Resistance Prostate Cancer
Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone
PROpel Phase III trial results show clinically meaningful benefit in patients
Glenmark Enters Agreement with Astrazeneca to Commercialize its product Pulmicort Respules in Colombia
Glenmark Pharmaceuticals, an innovation‐driven, global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals Colombia S.A.S. and Astrazeneca Colombia S.A.S. have entered into an exclusive licensing agreement for the commercialization of Astrazeneca's drug Pulmicort Respules®. Under the terms of the agreement,